SOG2 Antibody

What is SOG2 antibody and what are its primary research applications?

SOG2 antibody is a polyclonal antibody raised in rabbits against the recombinant Schizosaccharomyces pombe (strain 972/ATCC 24843) sog2 protein. This antibody is primarily used in fundamental research investigating protein expression and interactions in fission yeast models .

The antibody has been validated for use in Western blot (WB) and ELISA applications to ensure proper identification of the target antigen . As a research tool, SOG2 antibody facilitates the study of protein function and cellular processes in fission yeast, which serves as an important model organism in molecular and cellular biology research.

It's important to note that SOG2 antibody is designated for research use only and should not be employed in diagnostic or therapeutic procedures . This limitation aligns with standard practice for research-grade antibodies that have not undergone the rigorous validation required for clinical applications.

What are the key specifications of commercially available SOG2 antibody?

The following table outlines the key specifications of a commercially available SOG2 antibody:

Source: Cusabio product datasheet

How should SOG2 antibody be properly stored and handled?

Proper storage and handling of SOG2 antibody is crucial for maintaining its activity and specificity. Upon receipt, the antibody should be stored at either -20°C or -80°C . It's important to avoid repeated freeze-thaw cycles as these can degrade the antibody and reduce its efficacy in experimental applications.

The antibody is supplied in a storage buffer containing 50% glycerol, 0.01M PBS at pH 7.4, and 0.03% Proclin 300 as a preservative . This formulation helps maintain antibody stability during storage. When working with the antibody, consider the following handling recommendations:

• Aliquot the antibody upon first thaw to minimize freeze-thaw cycles

• Keep the antibody on ice when in use

• Return to -20°C or -80°C promptly after use

• Follow manufacturer guidelines for recommended dilutions in specific applications

• Document lot numbers, receipt dates, and freezer location for proper laboratory record-keeping

Proper storage and handling protocols significantly impact experimental reproducibility and reliability, which is especially important given that recent studies indicate more than 50% of commercial antibodies may fail in one or more applications .

What controls should be included when using SOG2 antibody in Western blot applications?

When designing Western blot experiments with SOG2 antibody, incorporating appropriate controls is essential for result validation. Based on best practices in antibody research, the following controls should be included:

• Positive control: Lysate from wild-type S. pombe cells expressing the sog2 protein

• Negative control: Lysate from a CRISPR-generated sog2 knockout (KO) S. pombe strain

• Loading control: Probing for a housekeeping protein to ensure equal sample loading

• Secondary antibody control: Omitting primary antibody to check for non-specific binding

• Specificity control: Pre-adsorption of the antibody with the immunizing antigen

The use of isogenic wild-type and knockout cell lines provides the most rigorous validation of antibody specificity . Studies have shown that this approach is superior to other validation methods, though it comes at a higher cost (approximately $25,000 per antibody characterization) . For SOG2 antibody, confirming specificity is particularly important since polyclonal antibodies may recognize multiple epitopes on the target protein and potentially cross-react with other proteins.

How can researchers optimize protocols for immunoprecipitation using SOG2 antibody?

While SOG2 antibody is not specifically validated for immunoprecipitation (IP) in the provided datasheet , researchers interested in adapting it for this application should consider the following optimization steps based on best practices for polyclonal antibodies:

• Buffer optimization: Test different lysis and washing buffers to maintain protein-antibody interactions while minimizing non-specific binding. Consider starting with non-denaturing cell lysates similar to validated antibody testing protocols .

• Antibody amount titration: Begin with manufacturer-recommended concentrations and adjust as needed. Typical starting points range from 1-5 μg antibody per 100-500 μg total protein.

• Cross-validation: Confirm IP results using Western blot with the same antibody or a different validated antibody against the same target . This approach helps verify that the immunoprecipitated protein is indeed sog2.

• Bead selection: Compare protein A/G beads, magnetic beads, and other immunocapture supports to determine optimal binding conditions for rabbit IgG.

• Pre-clearing lysates: Remove proteins that bind non-specifically to beads by pre-clearing lysates with beads alone before adding the antibody.

• Elution conditions: Optimize elution conditions to efficiently recover the target protein without co-eluting antibody chains.

When adapting antibodies for applications beyond their validated use, thorough optimization and validation become even more critical. Studies indicate that proper antibody characterization using engineered knockout cells significantly improves experimental reliability .

What are the recommended dilutions and incubation conditions for SOG2 antibody in Western blot applications?

• Primary antibody dilution: Begin with a 1:500 to 1:2000 dilution range in blocking buffer (typically 3-5% BSA or non-fat milk in TBST)

• Incubation conditions: Incubate membrane with primary antibody overnight at 4°C with gentle rocking, or for 1-2 hours at room temperature

• Washing steps: Wash membrane 3-5 times (5-10 minutes each) with TBST buffer after primary antibody incubation

• Secondary antibody: Use an anti-rabbit IgG HRP-conjugated secondary antibody at 1:5000 to 1:10000 dilution

• Detection method: Use enhanced chemiluminescence (ECL) or other compatible detection systems

To determine the optimal conditions, a titration series testing different antibody concentrations is recommended. Additionally, adjusting blocking conditions (buffer composition, blocking agent concentration) may help reduce background and improve signal-to-noise ratio. Document successful conditions thoroughly to ensure experimental reproducibility.

How does the polyclonal nature of SOG2 antibody affect experimental interpretation compared to monoclonal alternatives?

The polyclonal nature of SOG2 antibody has significant implications for experimental design and data interpretation. Unlike monoclonal antibodies, polyclonals contain a heterogeneous mixture of antibodies recognizing multiple epitopes on the target protein . This characteristic introduces both advantages and challenges:

Advantages of polyclonal SOG2 antibody:

• Recognition of multiple epitopes potentially increases signal strength

• Greater tolerance to minor changes in protein conformation

• Less sensitivity to epitope masking by protein-protein interactions

• Often more effective at detecting denatured proteins in Western blot applications

Challenges for experimental interpretation:

• Batch-to-batch variability can affect reproducibility

• Potential for cross-reactivity with related proteins

• May detect multiple isoforms or post-translational modifications

• Can produce higher background signals than monoclonal antibodies

Recent research indicates that recombinant antibodies generally outperform both monoclonal and polyclonal antibodies in specificity testing . Data from large-scale antibody validation studies showed that approximately 67% of recombinant antibodies successfully detected their targets in Western blot applications, compared to only 41% of monoclonals and 27% of polyclonals . Researchers should consider these performance differences when interpreting results and potentially validate critical findings with alternative detection methods.

What approaches should be used to validate SOG2 antibody specificity in novel experimental systems?

When employing SOG2 antibody in novel experimental systems beyond fission yeast, comprehensive validation is essential. Based on best practices in antibody research , the following validation approaches are recommended:

• Genetic validation: Generate CRISPR knockout cell lines lacking the target protein and compare antibody recognition patterns between wild-type and knockout samples. This represents the gold standard for antibody validation .

• Orthogonal validation: Compare antibody-based detection with an antibody-independent method such as mass spectrometry or RNA-seq to confirm target expression levels.

• Independent antibody validation: Use a second antibody targeting a different epitope on the same protein to confirm results.

• Recombinant expression: Overexpress tagged versions of the target protein and verify detection by both the tag-specific antibody and SOG2 antibody.

• Pre-adsorption test: Pre-incubate the antibody with purified antigen before application to verify that signal loss occurs when the antibody's binding sites are occupied.

When validating in new systems, researchers should be particularly careful to establish appropriate positive and negative controls. If extending studies beyond the validated fission yeast system, sequence homology analysis between S. pombe sog2 protein and potential target proteins should be conducted to assess the likelihood of cross-reactivity .

How can researchers address contradictory results when using SOG2 antibody across different experimental platforms?

When faced with contradictory results using SOG2 antibody across different experimental platforms (e.g., Western blot vs. ELISA), researchers should implement a systematic troubleshooting approach:

• Validate antibody performance in each application: Comprehensive validation should be performed for each experimental platform independently, as antibodies may perform differently across applications. Studies show that many antibodies fail in one or more applications despite working well in others .

• Consider epitope accessibility: The polyclonal nature of SOG2 antibody means it recognizes multiple epitopes, some of which may be accessible in certain experimental conditions but masked in others.

• Evaluate buffer compatibility: Different buffers used across experimental platforms may affect antibody binding characteristics.

• Check for interfering substances: Sample preparation methods for different platforms may introduce substances that interfere with antibody-antigen interaction.

• Implement quantitative controls: Include dilution series of recombinant target protein as quantitative controls across platforms.

• Cross-validate with orthogonal methods: Employ non-antibody-based detection methods to resolve contradictions.

A recent study examining hundreds of antibodies found that approximately 50-75% of human proteins could be detected by at least one high-performing antibody, depending on the application . This suggests that successful detection often depends on finding the optimal antibody-application pairing through systematic evaluation.

What statistical approaches are recommended for quantifying Western blot data using SOG2 antibody?

When quantifying Western blot data generated using SOG2 antibody, researchers should implement rigorous statistical approaches to ensure data reliability:

• Technical replicates: Perform at least three technical replicates per biological sample to account for variability in the Western blot procedure.

• Biological replicates: Include a minimum of three biological replicates to account for natural biological variation.

• Normalization strategy: Normalize target protein band intensity to a loading control (housekeeping protein) that remains stable across experimental conditions.

• Densitometry analysis: Use appropriate software (ImageJ, Bio-Rad Image Lab, etc.) for densitometric quantification of band intensity, being careful to subtract local background.

• Statistical testing: Apply appropriate statistical tests based on experimental design:

  • For comparing two groups: Student's t-test or Mann-Whitney U test

  • For multiple groups: ANOVA followed by post-hoc tests (Tukey, Bonferroni, etc.)

  • For non-normally distributed data: Non-parametric alternatives

• Effect size calculation: Report effect sizes (Cohen's d, fold change, etc.) alongside p-values.

• Visualization: Present data using dot plots or box-and-whisker plots showing individual data points rather than bar graphs with standard error bars alone.

Ensuring experimental reproducibility is particularly important given that a large number of published articles have used antibodies later found to be underperforming . Transparent reporting of antibody validation and quantification methods helps address this issue.

What are best practices for troubleshooting non-specific binding with SOG2 antibody?

Non-specific binding is a common challenge when working with polyclonal antibodies like SOG2. Implementing the following troubleshooting steps can help minimize this issue:

• Optimize blocking conditions: Test different blocking agents (BSA, non-fat milk, commercial blockers) and concentrations to reduce background.

• Adjust antibody concentration: Titrate primary antibody concentration to find the optimal balance between specific signal and background.

• Increase washing stringency: Extend washing times or increase detergent concentration in wash buffers.

• Pre-adsorb the antibody: Incubate with a lysate from cells lacking the target protein to remove antibodies that bind non-specifically.

• Optimize detection conditions: Reduce exposure time during imaging to minimize background signals.

• Check secondary antibody specificity: Test secondary antibody alone to verify it doesn't contribute to non-specific signals.

• Sample preparation: Ensure complete denaturation and reduction of samples for Western blot to improve epitope accessibility.

For challenging applications, consider implementing a sequential probing approach wherein secondary antibodies are completely stripped before reprobing with additional primary antibodies. This can help distinguish between true target signals and non-specific binding .

How does SOG2 antibody validation compare to standard validation procedures for research antibodies?

Evaluating how SOG2 antibody validation compares to best practices requires understanding current standards in antibody validation:

The gold standard for antibody validation involves testing in genetically modified cells where the target protein has been deleted (knockout) or significantly reduced (knockdown) . This approach provides the most rigorous assessment of antibody specificity by comparing signal between wild-type and knockout samples.

Recent large-scale studies have established that:

• Testing antibodies against isogenic wild-type and CRISPR knockout cell lines provides the most definitive validation

• Approximately 50% of commercial antibodies fail in one or more applications

• Multiple antibodies against the same target should be compared when possible

• Recombinant antibodies generally outperform monoclonal and polyclonal antibodies

When working with SOG2 antibody, researchers should consider implementing additional validation steps beyond manufacturer testing, particularly if using the antibody in critical research applications. Ideally, this would include testing against genetic knockout controls and orthogonal validation methods as described in section 3.2.

How might emerging antibody technologies improve upon current SOG2 antibody limitations?

Current SOG2 antibody, being polyclonal in nature , has inherent limitations including batch-to-batch variability and potential for cross-reactivity. Emerging antibody technologies offer several approaches that could address these limitations:

• Recombinant antibody production: Converting successful SOG2 antibody clones to recombinant format would provide renewable reagents with consistent performance. Recent studies demonstrate that recombinant antibodies outperform both monoclonal and polyclonal antibodies, with 67% of recombinant antibodies successfully detecting their targets in Western blot applications .

• Bispecific antibody engineering: Applying advanced bispecific antibody design principles could create more specific SOG2 detection reagents. These engineered antibodies can simultaneously target two epitopes, potentially increasing specificity and reducing background .

• Single-domain antibodies (sdAbs): Implementing sdAbs as fusion partners in antibody engineering could improve SOG2 antibody stability and reduce aggregation issues sometimes seen with traditional antibody formats .

• Optimized linker design: For engineered antibody formats, selecting appropriate glycine-serine linkers (10-25 amino acids) could improve flexibility and stability in aqueous solutions .

• In silico developability screening: Applying computational tools to screen for developability liabilities could improve SOG2 antibody formulations, addressing potential issues with expression yields and biophysical stability .

These technological advances align with broader efforts to improve antibody reproducibility and reliability in research applications.

What methodological considerations should be addressed when designing experiments to study potential cross-reactivity of SOG2 antibody?

When investigating potential cross-reactivity of SOG2 antibody with proteins other than its intended target, researchers should implement comprehensive methodological approaches:

• Sequence homology analysis: Compare the amino acid sequence of S. pombe sog2 protein with homologous proteins in experimental systems to identify regions of similarity that might lead to cross-reactivity.

• Epitope mapping: Determine which specific regions or epitopes of the sog2 protein are recognized by the antibody, which can help predict potential cross-reactivity.

• Panel testing: Test the antibody against a panel of related proteins to assess specificity boundaries.

• Competition assays: Perform assays where unlabeled target protein competes with potential cross-reactive proteins for antibody binding.

• Mass spectrometry validation: Use immunoprecipitation followed by mass spectrometry to identify all proteins captured by the antibody.

• Western blot comparison: Compare band patterns between samples containing or lacking the target protein, with particular attention to bands that appear in both samples.

• Genetic validation: Generate multiple knockout cell lines for the target and potential cross-reactive proteins to systematically assess antibody specificity.

This systematic approach aligns with best practices in antibody validation and can help researchers accurately interpret experimental results obtained using SOG2 antibody.